Harrow Inc (HROW)

$39.12 +0.96 (2.52%)
Market Cap 1.41B
Revenue (ttm) 199.61M
Net Income (ttm) -17.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 101.50
Profit Margin -8.76%
Debt to Equity Ratio 0.78
Volume 618,800
Avg Vol 516,424
Day's Range N/A - N/A
Shares Out 37.00M
Stochastic %K 86%
Beta 0.41
Analysts Strong Sell
Price Target $61.69

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
Finnish_boy
Finnish_boy Aug. 23 at 8:54 AM
$HROW B Riley estimates dont assume reaching their 250m quarter guidance in 2027. And PT still $65. Estimate of 2027 revenue should be 100-150m more in order to hit the goal. I think Harrow hits that very likely after new acquisitions, already in Q3 2027. Can be that Q1 2028 is not over 250m but total revenue for 2028 will be >1B imho. So basically mgt has guided >1B for 2028.
1 · Reply
Finnish_boy
Finnish_boy Aug. 23 at 6:59 AM
$HROW This traded like xbi/ other similar stocks. They were sold down before the close. Think next week we will have solid run despite of other stocks.
0 · Reply
Finnish_boy
Finnish_boy Aug. 22 at 7:47 PM
$HROW Okay, this month PT $42.. next month $50.. come on markets. Stupid cheap.
1 · Reply
wallstpirate
wallstpirate Aug. 22 at 3:36 PM
$HROW Baum looks like a genious now with rate son tap to be lowered and he backing off sales rep to increase ebitda.
1 · Reply
Finnish_boy
Finnish_boy Aug. 22 at 3:00 PM
$HROW Baum called Powell to lower rates due to refi. Lets goo. Russell skyrockets.
0 · Reply
Finnish_boy
Finnish_boy Aug. 22 at 2:54 PM
$HROW Very green day for everyone. Harrow will go much up before investor day. Lets go. Does someone own HITI? Pretty nice run up. I bought luckily more it a week ago
2 · Reply
Finnish_boy
Finnish_boy Aug. 22 at 11:06 AM
$HROW B Riley has $747M for 2028 and PT $65.. Harrow guides >$1B.. what the PT should be? Lets say $100 PT. Waiting game now. Investor day 26th September big day.!
1 · Reply
Finnish_boy
Finnish_boy Aug. 22 at 10:45 AM
$HROW "So basically they're looking for 60% revenue CAGR and trading at just 4.8x sales which is quite rare." Just wait. This is unreal. SP going to skyrocket in a year.
0 · Reply
CoyoteUgly
CoyoteUgly Aug. 21 at 2:45 PM
$HROW
0 · Reply
wallstpirate
wallstpirate Aug. 21 at 2:41 PM
$HROW From BRiley Improving Multi-Product Launch Dynamics Lends Credibility to LT Target Model; Up Next 9/26 Analyst Day; Reiterate Buy, $65 PT. I cannot post the pdf.
0 · Reply
Latest News on HROW
Harrow's Ambitious Guidance Puts It In The Proving Ground

Aug 14, 2025, 11:09 PM EDT - 8 days ago

Harrow's Ambitious Guidance Puts It In The Proving Ground

Harrow: Exciting Times In Store

Aug 13, 2025, 5:39 PM EDT - 10 days ago

Harrow: Exciting Times In Store

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 2:47 PM EDT - 11 days ago

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Harrow Announces Second-Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 12 days ago

Harrow Announces Second-Quarter 2025 Financial Results

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Aug 6, 2025, 7:00 AM EDT - 17 days ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 29, 2025, 7:00 AM EDT - 25 days ago

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 5 weeks ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 5 weeks ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Jul 15, 2025, 10:38 AM EDT - 5 weeks ago

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Jul 11, 2025, 5:47 PM EDT - 6 weeks ago

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Harrow: Immense Upside Potential

Jul 9, 2025, 2:52 PM EDT - 6 weeks ago

Harrow: Immense Upside Potential

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 18, 2025, 7:00 AM EDT - 2 months ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

I Am Swimming In Dividends With +7% Yields

Jun 13, 2025, 8:30 AM EDT - 2 months ago

I Am Swimming In Dividends With +7% Yields

UMH

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Jun 9, 2025, 7:00 AM EDT - 2 months ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Harrow: Epic Growth & Operating Leverage On Full Display

May 28, 2025, 3:20 PM EDT - 3 months ago

Harrow: Epic Growth & Operating Leverage On Full Display

Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 3 months ago

Harrow to Present at Two Investor Conferences in May

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 10, 2025, 6:17 PM EDT - 3 months ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 3 months ago

Harrow Announces First-Quarter 2025 Financial Results

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

May 5, 2025, 7:00 AM EDT - 3 months ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 4 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Apr 10, 2025, 7:00 AM EDT - 4 months ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 29, 2025, 4:30 PM EDT - 5 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 2:00 PM EDT - 5 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Mar 28, 2025, 1:39 PM EDT - 5 months ago

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 4:01 PM EDT - 5 months ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 27, 2025, 10:45 AM EDT - 5 months ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 24, 2025, 7:00 AM EDT - 5 months ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 4:01 PM EDT - 5 months ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow Launches VEVYE® Access for All

Mar 17, 2025, 7:00 AM EDT - 5 months ago

Harrow Launches VEVYE® Access for All

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Mar 11, 2025, 7:00 AM EDT - 5 months ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Mar 3, 2025, 7:15 AM EST - 6 months ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Mar 1, 2025, 8:50 AM EST - 6 months ago

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Jan 27, 2025, 7:30 AM EST - 7 months ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

COR

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Jan 7, 2025, 7:00 AM EST - 8 months ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Those Derisked Baby Bonds Of Harrow, Inc.

Jan 3, 2025, 3:43 PM EST - 8 months ago

Those Derisked Baby Bonds Of Harrow, Inc.

Harrow: The Triesence Relaunch

Dec 14, 2024, 12:09 AM EST - 9 months ago

Harrow: The Triesence Relaunch

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Nov 21, 2024, 7:00 AM EST - 9 months ago

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Harrow Announces Participation in Upcoming Investor Conferences

Nov 15, 2024, 7:00 AM EST - 10 months ago

Harrow Announces Participation in Upcoming Investor Conferences

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 2:56 PM EST - 10 months ago

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Harrow Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:34 PM EST - 10 months ago

Harrow Announces Third Quarter 2024 Financial Results

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

Nov 13, 2024, 7:00 AM EST - 10 months ago

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

GDRX

Harrow Announces Market Access Wins for VEVYE®

Nov 12, 2024, 7:00 AM EST - 10 months ago

Harrow Announces Market Access Wins for VEVYE®

Harrow: VEVYE And Its Impact On The DED Market

Nov 11, 2024, 6:37 AM EST - 10 months ago

Harrow: VEVYE And Its Impact On The DED Market

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products

Nov 7, 2024, 7:00 AM EST - 10 months ago

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

Oct 31, 2024, 7:00 AM EDT - 10 months ago

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

I Am Banking On The Silver Tsunami With Big Dividends

Oct 12, 2024, 10:30 AM EDT - 11 months ago

I Am Banking On The Silver Tsunami With Big Dividends

THQ XOMA

Harrow Relaunches TRIESENCE®

Oct 3, 2024, 7:00 AM EDT - 11 months ago

Harrow Relaunches TRIESENCE®

Finnish_boy
Finnish_boy Aug. 23 at 8:54 AM
$HROW B Riley estimates dont assume reaching their 250m quarter guidance in 2027. And PT still $65. Estimate of 2027 revenue should be 100-150m more in order to hit the goal. I think Harrow hits that very likely after new acquisitions, already in Q3 2027. Can be that Q1 2028 is not over 250m but total revenue for 2028 will be >1B imho. So basically mgt has guided >1B for 2028.
1 · Reply
Finnish_boy
Finnish_boy Aug. 23 at 6:59 AM
$HROW This traded like xbi/ other similar stocks. They were sold down before the close. Think next week we will have solid run despite of other stocks.
0 · Reply
Finnish_boy
Finnish_boy Aug. 22 at 7:47 PM
$HROW Okay, this month PT $42.. next month $50.. come on markets. Stupid cheap.
1 · Reply
wallstpirate
wallstpirate Aug. 22 at 3:36 PM
$HROW Baum looks like a genious now with rate son tap to be lowered and he backing off sales rep to increase ebitda.
1 · Reply
Finnish_boy
Finnish_boy Aug. 22 at 3:00 PM
$HROW Baum called Powell to lower rates due to refi. Lets goo. Russell skyrockets.
0 · Reply
Finnish_boy
Finnish_boy Aug. 22 at 2:54 PM
$HROW Very green day for everyone. Harrow will go much up before investor day. Lets go. Does someone own HITI? Pretty nice run up. I bought luckily more it a week ago
2 · Reply
Finnish_boy
Finnish_boy Aug. 22 at 11:06 AM
$HROW B Riley has $747M for 2028 and PT $65.. Harrow guides >$1B.. what the PT should be? Lets say $100 PT. Waiting game now. Investor day 26th September big day.!
1 · Reply
Finnish_boy
Finnish_boy Aug. 22 at 10:45 AM
$HROW "So basically they're looking for 60% revenue CAGR and trading at just 4.8x sales which is quite rare." Just wait. This is unreal. SP going to skyrocket in a year.
0 · Reply
CoyoteUgly
CoyoteUgly Aug. 21 at 2:45 PM
$HROW
0 · Reply
wallstpirate
wallstpirate Aug. 21 at 2:41 PM
$HROW From BRiley Improving Multi-Product Launch Dynamics Lends Credibility to LT Target Model; Up Next 9/26 Analyst Day; Reiterate Buy, $65 PT. I cannot post the pdf.
0 · Reply
Finnish_boy
Finnish_boy Aug. 21 at 2:39 PM
$HROW B Riley: "Improving Multi-Product Launch Dynamics Lends Credibility to LT Target Model; Up Next 9/26 Analyst Day; Reiterate Buy, $65 PT"
0 · Reply
Finnish_boy
Finnish_boy Aug. 21 at 5:24 AM
$HROW My all stocks' stories going really well. #1 HROW.. next year PE 15 with 40% growth.. wake up markets #2 GOSS.. insider bought yesterday, 5x opportunity in a year, ph3 readout in February, risky but incredible R/R #3 HITI.. entered Germany, stupid cheap stock #4 IREN.. signing first data center deal in Q4 #5 GLNG.. two new projects coming in a year, no position atm
1 · Reply
Finnish_boy
Finnish_boy Aug. 20 at 7:21 PM
$HROW Hammer on pullback, should be lower low. Then up. I expect some partnership deal before sept 26th investor day. SP should be now over $70 but looks like markets dont care about this stock.
2 · Reply
stockinvestor102
stockinvestor102 Aug. 20 at 3:24 PM
$HROW bought a small amount of shares.
1 · Reply
Huntergame
Huntergame Aug. 20 at 2:02 PM
$HROW slow bleeding everyday, so it will happen again? The little uptrend disappears again slowly…
0 · Reply
Finnish_boy
Finnish_boy Aug. 20 at 7:07 AM
$HROW Remember that August-September is weaker time for stock markets. And take into account that indexes are at all time high so healthy pullback is normal. There will be no inflation problem or downturn in US economy. But ofc everything can happen. No one knows the future. But i expect strong Q4 and strong next year. I have actually quite big positive risk that indexes will go to bubble. The best (imo) finnish macro analyst /trader made his prediction about a week ago: But anyways, HROW will go up. This year new ATH and next year over $100 levels.
2 · Reply
mutallim
mutallim Aug. 20 at 5:38 AM
Guys here is new gem for long : $HROW
0 · Reply
Finnish_boy
Finnish_boy Aug. 20 at 5:10 AM
$HROW Big opportunity. Markets are not sleeping, they dont care.
0 · Reply
Finnish_boy
Finnish_boy Aug. 19 at 8:54 PM
$HROW I dont see any impact on iheezo actually. This is like more efficient eye numbing drop than lidocaine / others.. and not sure about side effect profile vs lidocaine/ others.. but yea, imo no impact on iheezo but i can be wrong also. iheezo btw over 500m drug.
0 · Reply
Finnish_boy
Finnish_boy Aug. 19 at 7:25 PM
$HROW Nice find from @tupelo3.. never heard about articaine ophthalmic solution.. but according GROK Iheezo has better effiacy, better tolerability, and better duration. But i am not 100% sure. So likely there is now better option for lidocaine/propaceine whatever the name was. But iheezo is the best option for many use of cases + financial incentive to use it.
0 · Reply
Finnish_boy
Finnish_boy Aug. 19 at 6:49 PM
$HROW i hate investing when i have to read things like this, looks like there now better 2nd option, not 100% sure.. does this affect on iheezo, likely not. what others think? iheezo has own advantages. i am not worried but if someone is, comment below.
2 · Reply
Finnish_boy
Finnish_boy Aug. 19 at 6:33 PM
$HROW Tomorrow someone posts that taiwanese launched the drug called vevsee, effiacy 2x compared to vevye
0 · Reply